
Jian Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1007069/publications.pdf Version: 2024-02-01



LIAN WANC

#	Article	IF	CITATIONS
1	Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5ã€A3 genetic locus and lung cancer risk. Cancer, 2010, 116, 3458-3462.	4.1	67
2	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nature Communications, 2019, 10, 448.	12.8	65
3	Genetic Variations in Interleukin-8 and Interleukin-10 Are Associated With Pain, Depressed Mood, and Fatigue in Lung Cancer Patients. Journal of Pain and Symptom Management, 2013, 46, 161-172.	1.2	57
4	Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Science Advances, 2021, 7, .	10.3	54
5	Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction. BMC Systems Biology, 2015, 9, 25.	3.0	43
6	Estimation of odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Genetic Epidemiology, 2011, 35, 190-200.	1.3	37
7	Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. Cancer, 2020, 126, 5124-5136.	4.1	30
8	Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS ONE, 2017, 12, e0180396.	2.5	27
9	MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients. BMC Genetics, 2016, 17, 40.	2.7	25
10	Method for Evaluating Multiple Mediators: Mediating Effects of Smoking and COPD on the Association between the CHRNA5-A3 Variant and Lung Cancer Risk. PLoS ONE, 2012, 7, e47705.	2.5	23
11	Genome-wide association study suggests common variants within RP11-634B7.4 gene influencing severe pre-treatment pain in head and neck cancer patients. Scientific Reports, 2016, 6, 34206.	3.3	12
12	Power and type I error results for a bias-correction approach recently shown to provide accurate odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Genetic Epidemiology, 2011, 35, 739-743.	1.3	11
13	Estimation of indirect effect when the mediator is a censored variable. Statistical Methods in Medical Research, 2018, 27, 3010-3025.	1.5	6
14	Mediation analysis in a caseâ€control study when the mediator is a censored variable. Statistics in Medicine, 2019, 38, 1213-1229.	1.6	5
15	Processing and Analyzing Human Microbiome Data. Methods in Molecular Biology, 2017, 1666, 649-677.	0.9	4
16	Longitudinal associations of family functioning with body mass index in Mexican-origin adolescents living in the U.S Preventive Medicine, 2019, 118, 309-316.	3.4	4
17	An Approach to Analyze Longitudinal Zero-Inflated Microbiome Count Data Using Two-Stage Mixed Effects Models. Statistics in Biosciences, 2021, 13, 267-290.	1.2	3
18	Mediation model with a categorical exposure and a censored mediator with application to a genetic study. PLoS ONE, 2021, 16, e0257628.	2.5	2

#	Article	IF	CITATIONS
19	A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules. Statistics in Medicine, 2021, 40, 4629-4639.	1.6	Ο